Danish Oil and Gas Stock News

MT Højgaard Holding (CPSE:MTHH) has put fresh numbers on the table for FY 2025, with Q4 revenue of DKK 2.5b and basic EPS of DKK 10.08 alongside net income from continuing operations of DKK 77.7m. Over recent quarters the company has seen revenue move between DKK 2.4b and DKK 3.1b and quarterly EPS range from DKK 9.13 to DKK 14.81, which sets expectations around how a trailing net margin of 3.1% will shape investor views on the quality and resilience of those earnings. See our full analysis...

Q1 earnings as the key trigger Novozymes (CPSE:NSIS B) is back in focus after reporting first quarter 2026 results, with sales of €1,119.3 million and net income of €199.1 million compared with the same period a year earlier. See our latest analysis for Novozymes. The Q1 release appears to have steadied sentiment, with a 1-day share price return of 2.25% partly offsetting weaker recent momentum, including a 1-year total shareholder return of 12.68% and a 5-year total shareholder return of...

Genmab (CPSE:GMAB) has drawn fresh attention after its first quarter 2026 report, where sales reached US$896 million but net income dropped to US$53 million, alongside a negative immediate share price reaction. See our latest analysis for Genmab. The weak 1 day share price return of 6.74% and 30 day share price return of 8.30% follow a Q1 update where revenue moved higher but net income declined sharply, leaving the current share price at DKK1,640. Over a longer horizon, the 1 year total...

Why Vizient’s contract matters for Coloplast (CPSE:COLO B) Coloplast (CPSE:COLO B) just secured an Innovative Technology contract with Vizient for its Biatain Silicone Fit wound dressing, putting the product in front of a broad network of US hospitals and care providers. This recognition reflects feedback from Vizient’s client-led councils and signals that Biatain Silicone Fit has characteristics US healthcare buyers consider differentiating. This development could influence how investors...

If you are wondering whether Pandora at DKK 537.6 is priced for a recovery or still carries more risk than reward, this breakdown will help you frame what the current share price might be implying. The stock has returned 8.2% over the last week and 14.0% over the last month, set against a year-to-date return of a 22.7% decline and a 45.4% decline over the last year. Recent coverage around Pandora has focused on whether the current share price aligns with its fundamentals, as investors weigh...

A.P. Møller & Co. Mærsk (CPSE:MAERSK B) is back in focus after first quarter 2026 results showed profit pressure alongside higher fuel and operating costs linked to Middle East disruptions, including the war in Iran and constrained shipping routes. See our latest analysis for A.P. Møller - Mærsk. The stock has pulled back recently, with a 7 day share price return of 7.22% and a 30 day share price return of 11.34% after the weaker Q1 net income and rising fuel costs. However, the 1 year total...

Shareholders might have noticed that Ørsted A/S ( CPH:ORSTED ) filed its quarterly result this time last week. The...

Shareholders might have noticed that GN Store Nord A/S ( CPH:GN ) filed its first-quarter result this time last week...

As you might know, Ambu A/S ( CPH:AMBU B ) last week released its latest quarterly, and things did not turn out so...

Why Jyske Bank’s latest earnings matter for shareholders Jyske Bank (CPSE:JYSK) just released first quarter 2026 results, giving you fresh insight into how the bank is handling weaker net interest income and net income while keeping capital and fee income on a firm footing. See our latest analysis for Jyske Bank. Despite the softer Q1 figures, the stock’s 1 year total shareholder return of 56.04% and 5 year total shareholder return of 217.03% contrast with a recent 9.49% 3 month share price...

Novo Nordisk recently reported first‑quarter 2026 results showing sales rising to DKK 96,823 million and net income to DKK 48,557 million, driven largely by surging demand for its new oral Wegovy weight‑loss pill, which has passed two million U.S. prescriptions since its January launch. This launch is being described as the strongest-ever U.S. obesity drug debut by volume, prompting Novo Nordisk to raise its 2026 guidance for adjusted sales and operating profit as oral GLP‑1 treatments...

Genmab (CPSE:GMAB) opened 2026 with Q1 revenue of US$896 million and basic EPS of US$0.84, setting the tone for how the market will judge its current earnings run versus earlier quarters. Over the past year, reported quarterly revenue has ranged from US$715 million to just over US$1.0 billion, while basic EPS has moved between US$0.50 and US$9.10. This gives you a wide band of outcomes to weigh against the trailing 12 month EPS of US$13.24 and net income of US$821 million. With net margins in...

Solar (CPSE:SOLAR B) has opened 2026 with Q1 revenue of DKK 3.3b and a basic EPS loss of DKK 5.28, while the trailing twelve months show EPS of DKK 7.81 on revenue of DKK 12.3b and net income of DKK 59m. This sets a mixed backdrop for the latest release. Over recent quarters, the company has seen revenue move from DKK 3.2b in Q1 2025 to DKK 3.3b in Q1 2026, with quarterly EPS swinging between a profit of DKK 12.99 in Q4 2025 and a loss of DKK 5.28 in the latest period. With net profit margins...

The quarterly results for Netcompany Group A/S ( CPH:NETC ) were released last week, making it a good time to revisit...

Shareholders of Pandora A/S ( CPH:PNDORA ) will be pleased this week, given that the stock price is up 12% to kr.541...

Vestas Wind Systems A/S ( CPH:VWS ) just released its quarterly report and things are looking bullish. The company beat...

Zealand Pharma (CPSE:ZEAL) opened Q1 2026 with revenue of DKK 34 million, a basic EPS loss of DKK 5.58 and net income loss of DKK 394 million, setting a very different tone against the backdrop of a trailing twelve month EPS of DKK 90.74 and net income of DKK 6.4b. Over recent quarters the company has seen revenue move from DKK 8.09 million in Q1 2025 to DKK 9.06 million in Q4 2024 and then up to DKK 9.09b in Q2 2025, while quarterly EPS has swung from a loss of DKK 4.11 in Q4 2024 to a...

Trifork Group AG ( CPH:TRIFOR ) just released its latest first-quarter report and things are not looking great. It...

As you might know, DFDS A/S ( CPH:DFDS ) recently reported its first-quarter numbers. Revenues were kr.7.4b, with DFDS...

A.P. Møller - Mærsk (CPSE:MAERSK B) opened 2026 with Q1 revenue of about US$13.0b, Basic EPS of US$4, and net income of US$53m, setting a measured tone for the new financial year. The company’s quarterly revenue moved from about US$14.6b in Q4 2024 to roughly US$13.3b in Q1 2025 and then to about US$13.0b in Q1 2026. Over the same period, Basic EPS shifted from US$131.42 in Q4 2024 to US$74.00 in Q1 2025 and then to US$4 in Q1 2026. These shifts feed directly into how you might think about...

Ørsted (CPSE:ORSTED) opened 2026 with Q1 revenue of DKK 27.6b and basic EPS of DKK 1.6, setting a clear marker after a volatile run of quarterly results. The company has seen quarterly revenue move from DKK 20.7b in Q1 2025 to DKK 27.6b in Q1 2026, while EPS shifted from DKK 10.57 a year ago through several loss making quarters to DKK 1.6 this quarter. This gives investors a fresh read on how margins are shaping up after a period of trailing 12 month losses and forecasted earnings growth...

AL Sydbank (CPSE:ALSYDB) opened 2026 with Q1 revenue of DKK 2.9b and basic EPS of DKK 9, alongside trailing 12 month revenue of DKK 9.5b and EPS of DKK 32.39 that reflect a mixed year including a large one off loss. The company has seen quarterly revenue range from DKK 1.6b in Q4 2024 to DKK 3.2b in Q4 2025, while basic EPS has swung between DKK 6.88 and a small loss of DKK 0.64 over that span. This context sets the stage for investors to focus on how current profit margins compare with last...

GN Store Nord (CPSE:GN) opened Q1 2026 with revenue of DKK2.1b and basic EPS of DKK3.06, with earnings from discontinued operations contributing a loss of DKK509m and net income excluding extra items at a loss of DKK446m. Over recent periods, the company has seen quarterly revenue move from DKK5.0b in Q4 2024 to DKK4.7b in Q4 2025 and DKK2.1b in Q1 2026, with basic EPS shifting from DKK2.52 in Q4 2024 to DKK2.36 in Q4 2025 and then to a loss of DKK3.06 in the latest quarter. This puts the...

If you are wondering whether Aktieselskabet Schouw is fairly priced or offering value at its current level, it helps to break the stock down using a few clear valuation angles. The stock last closed at kr665.0, with returns of 2.0% over 7 days, 0.8% over 30 days, 0.2% year to date, 23.2% over 1 year, 27.0% over 3 years and 9.8% over 5 years. This gives you a sense of how the recent share price has behaved across different time frames. Recent news coverage around Aktieselskabet Schouw has...